Indeed, the Kenya Ministry selleck kinase inhibitor of Public Health and Sanitation intends to introduce rotavirus vaccine by 2013. The trial (Merck protocol V260-015) was funded by PATH’s Rotavirus Vaccine Program with a grant from the GAVI Alliance; the trial was co-sponsored by Merck & Co., Inc. This study, under protocol V260-015, was designed, managed, conducted, and analyzed by the co-sponsors in collaboration with the site

investigators and under the supervision and advice of the Data and Safety Monitoring Board. We wish to thank the study participants and their families, and the entire study team. We wish to acknowledge the assistance from the KEMRI/CDC HIV laboratory Selleckchem Dabrafenib for all HIV diagnostic testing, and the CDC GAP team for assistance in linking the study participants to appropriate HIV care and treatment. We are grateful to Michael J. Dallas and Donna Hyatt at Merck for numerous additional data analyses, and we also thank Michele L. Coia, and Margaret Nelson, also at Merck. We appreciate the support received from Kristen Lewis, J.C. Victor, and A. Duncan Steele at PATH. This manuscript is published with the permission of the

Director, KEMRI. KEMRI/CDC is a member of the INDEPTH Network. Conflict of interest statement: SBR is an employee of Merck and Co., and may own shares in the company. MC was an employee of Merck & Co., and owned shares in the company when

the study was conducted. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. No other conflicts of interest are reported. “
“Diarrheal diseases constitute Florfenicol one of the top two killers of infants and young children <5 years of age worldwide, the vast majority occurring in developing countries [1]. It has been estimated that each year rotavirus gastroenteritis (RVGE) is responsible for approximately 2 million hospitalizations and 453,000 deaths among children <5 years, representing 37% of all deaths due to diarrhea in this age group [2]. Although rotavirus (RV) vaccines had been shown to be highly efficacious in preventing severe RVGE in infants and toddlers in industrialized countries [3] and [4], their efficacy in infants and young children in the developing world was questioned by the World Health Organization (WHO). Differences in host populations (e.g., differences in the gut microbiome), associated health conditions (e.g.